Overall and progression-free survival by subgroups. (A) Progression free survival (PFS) by NCI-WG response for relapsed/refractory patients treated with FCR (n = 267). Early deaths (n = 13) shown in panel B. (B) Overall survival (OS) by NCI-WG response for relapsed and refractory patients treated with FCR (n = 280). Four patients were not evaluable for response. (C) PFS by karyotype for relapsed/refractory patients treated with FCR (n = 182). (D) OS by karyotype for relapsed/refractory patients treated with FCR (n = 182). CR indicates complete remission; nPR, nodular PR; PR, partial remission; NR, no objective response; ED, early death; Chr 17, chromosome 17 abnormalities; 11q−, 11q deletion; +12, trisomy 12; and Dip/13q−, diploid or 13q deletion.